03May 2019

NEOADJUVANT CHEMOTHERAPY BEFORE, CONCURRENTLY WITH AND AFTER RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER.

  • Clinical Oncology Department, Faculty of Medicine, Alexandria University, Egypt.
  • General Surgery Department, Faculty of Medicine, Alexandria University, Egypt.
  • Pathology Department ,Faculty of Medicine, Alexandria University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Purpose:Neoadjuvantchemoradiotherapy (CRT) has a major impact in the local control of locally advanced rectal cancer (LARC). However, distant metastases is still a major challenge. One approach to address this issue is early administration of systemic chemotherapy. The purpose of this phase II study is to evaluate the feasibility and efficacy of short course of induction chemotherapy in LARC patients treated with standard preoperative CRT. Methods and Mareials: Sixty-four patients with LARC were treated with two cycles of XELOX (capecitabine 1000 mg/m2 bid on days 1?14 and oxaliplatin 130 mg/m2 on day 1). One cycle of XELOX is given before CRT, while the second one is given in the resting period before surgery. During chemoradiation, blous 5-Fluorouracil 425 mg/m2 was dministered in the first 4 days and last 3 days of radiatation (50.4 Gy over 6 weeks ). Surgery was recommended 6 to 8 weeks after completion of CRT, followed by 4 four cycles of adjuvat XELOX. Results: Fifty-six patients underwent surgery; The pathological complete recponse (pCR) rate was seen in 16 (28.6%) patients, R0 resection was achieved in 54 (94.6%) patients. Tumor and nodal downstaging were observed in 40 (71.4%) and 25 (44.6 %) patients, respectively. Sphincter preservation was achieved in 44(78.6%) patients. Three year disease-free survival was 70.3 %, and overall survival was 82.8%. Conclusion: one cycle of XELOX before and after radiotherapy concurrent with 5-flourouracil for LARC results in a reasonable pCR, R0 resection and sphincter preservation, with acceptable safety and tolerability.

  1. Siegel R, Naishadham D, Jemal A. Cancer Statistics.CA Cancer J Clin 2013;63:11-30.
  2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-40.
  3. Guckenberger M, Saur G, Wehner D, Sweeney RA, Thalheimer A, Germer CT, Flentje H. Comparison of preoperative short- course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. StrahlentherOncol 2012; 188:551-57.
  4. Peeters KC, Marijen CA, Nagtegaal ID, kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow up of 6 years: increased local control but no survival benefit in irradiated patiets with resectable rectal carcinoma. Ann Surg 2007; 246:693-701.
  5. Kapiteijn E, Marijne CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46
  6. G?rard JP, Conroy T, Bonnetain F, Bouch? O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J ClinOncol 2006; 24:4620-25.
  7. Rodel C, Liersch T, Herman RM, Arnold D, Reese T, Hipp M, et al. Multicnter phase II tial of chemradiation with oxaliplatin for rectal cancer. J ClinOncol 2007; 25:110-17.
  8. Rodel C, Arnold D, Becker H, Fietkau R, Ghadimi M, Graeven U, et al. Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer. Is it time for a randomized phase III tial? StrahlentherOnkol 2010; 180(12): 658-90.
  9. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254:97-102.
  10. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao Juliao GP, Gama-Rodrigues J, et al. Increasing the rates of complete response to neoadjuvantchemoradiotherapy for distal rectal cancer :results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009; 52:1927-34.
  11. Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: Should we be more cautious? Br J Cancer 2006; 94:363-71.
  12. Schou JV, Larsen FO, Rasch L, Linneman D, Langoff J, H?gdal E, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.AnnOncol 2012; 23:2627-33.
  13. Marechel R, Vos B, Polu M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012; 23:1525-30.
  14. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging- defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J ClinOncol 2010;28:859-65.
  15. Chau YJ, Barbachano Y, Cunningham D,Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvantcapecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer :a phase 2 trial. Lancet Oncol 2010; 11(3):241-48.
  16. Koeberle D, Burkhard R, Von Moos R, Winterhalder R, Hess V, Heitzman F, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 2008; 98 (7):1204-9
  17. Garajova I, Di Girolamo S, de Rosa F, Corbelli J, Agostini V, Biasco G, et al. Neoadjuvant treatment in rectal cancer : actual status. Chemother Res pract. 2011; 2011:839742.
  18. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Published: May 28,2009:http :// evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-22.Accepted 21 NOV 2011
  19. Washington MK, Berlin J, Branton P, Bugart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009; 133:1539?51.
  20. Trakarnsanga A, G?nen M, Shia J, Nash GM, Temple LK, Guillem JG, et al. Comparison of tumor regression Grade Systems for locally Advanced rectal cancer After Multimodality treatment. JNCI J Natl Cancer Inst 2014;106 (10): dju248
  21. American Joint Committee on cancer. AJCC Cancer staging Manual. 7th New York: Springer; 2010.
  22. Hall MD, Schultheiss TE, Smith DD, Fakih MG, Kim J, Wong JY, et al. Impact of total lymph node count on staging and survival after neoadjuvantchemoradiation therapy for rectal cancer. Ann surgOncol 2015; 22:580-87.
  23. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-23.
  24. Rodel C, Lierch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer : initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679-87.
  25. Zampino MG, Magni F, Leonardi MC, Petazzi E, Santoro L, Luca F, et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J RadiatOncolBiolPhys 2009; 75:421-27.
  26. Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Stadler ZK, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery in the management of locally advanced rectal cancer. JNCCN 2014 ; 4:513-19.
  27. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvantcapecitabine and oxaliplatin followed by synchronuschemoradiation and total mesorectal excision in magnetic resonance imaging - defined poor -risk rectal cancer. J ClinOncol 2006;24:668-74.
  28. Gao YH, Lin JZ, An X, Luo JL, Cai MY, Cai PQ, et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectsl cancer. Int J RadiatOncolBiolPhys 2014; 90:1153-60
  29. Achele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR- 01 randomized phase III trial. J ClinOncol 2011; 29 :2773-80.
  30. An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, et al. Short term results of neoadjuvantchemoradiotherapy with fluoropyrimidine alone or in combination with oxalipltin in locally advanced rectal cancer :a meta analysis. EurJCancer 2013;49:843-51.
  31. Calvo FA, Serrano FJ, Diaz-Gonzalez JA, Gomez-Esp M, Lozano E, Garcia R, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol 2006; 17:1103?10.
  32. Finn OL, Alice M, Benny VJ, et al.Capecitabine and oxaliplatinbefore,during, and after radiotherapy for high-risk rectal cancer.Clin Colorectal Cancer 2016;16:7-14
  33. Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, et al. Complete pathologic response after combined modality treatment for rectal cancer and response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann SurgOncol 2012;19:2822-32
  34. Bouzourene H, Bosman FT, SeelentagW,et al. Importance of tumor regression assessment in predicting the outcome of patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121?30
  35. Chapet O, Romestaing P, Mornex F, Souquet JC, Favrel V, Ardiet JM, et al. Preoperative radiotherapy for rectal adenocarcinoma: which are strong prognostic factors? Int J RadiatOncolBiolPhys 2005; 61:1371?77.
  36. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J ClinOncol 2005; 23: 8688?96.

[Azza M Darwish, Ahmed Abdel latif And Dina Abdallah. (2019); NEOADJUVANT CHEMOTHERAPY BEFORE, CONCURRENTLY WITH AND AFTER RADIOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER. Int. J. of Adv. Res. 7 (May). 86-96] (ISSN 2320-5407). www.journalijar.com

Azza Darwish
Lecturer, Clinical Oncology Department (ACOD) Faculty of Medicine, Alexandria University Champlion Street, Alazarita, Alexandria 21131, Egypt

DOI:

Article DOI: 10.21474/IJAR01/9007      
DOI URL: http://dx.doi.org/10.21474/IJAR01/9007

Download Full Paper

Download PDF No. of Downloads: 14 | No. of Views: 77